Both companies have a common goal of providing high quality drug and device development services to their clients, from drug formulation through all phases of clinical trials in all ocular pathologies, including glaucoma, dry eye, anti-inflammatory and age-related macular degeneration. "The combined infrastructure of the two companies will allow us to achieve our customer's strategic goals on a global basis. "Iris is an excellent company with a great reputation. We are anxious to use our partnership with Iris to improve our customers' ability to develop innovative products and preserve vision around the world." said Drey Coleman, Managing Partner of Oculos.
"We have been exploring several opportunities to consolidate our presence in the US and Oculos appears to be a perfect partner for us at a stage where we are experiencing a rapid growth" says Pierre-Paul Elena, CEO of Iris Pharma. "We have a lot of confidence in Oculos' wide range of quality services for ophthalmic drug and device development. We are excited to work with the Oculos team, and to intensify our integrated preclinical and clinical development services capacity to support FDA and EMA submissions of ocular products", added Yann Quentric, Head of Business Development at Iris Pharma.
The companies will be exhibiting at ARVO 2015 in Denver, CO:
Iris Pharma booth#2818
About Oculos Clinical Research
Oculos Clinical Research is a full-service, ophthalmology-focused CRO with headquarters in Tampa, Florida. Oculos experience team provides a wide range of services in the area of CMC, Regulatory Affairs, Medical Writing and all phases of clinical development.
About Iris Pharma
Iris Pharma is an independent full-service CRO with headquarters in Nice, France. As a leading CRO dedicated to ophthalmology, Iris Pharma helps clients around the world navigate every stage of the drug and medical device development process– including ocular efficacy studies, Good Laboratory Practice (GLP) preclinical studies, bioanalysis, clinical trials, and marketing surveys. Iris Pharma has partnered with clients to bring nearly 70 ocular drugs and medical devices to market in the past 26 years, and offers consulting services to help clients determine the best indication for molecules and products in development.